This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about C-X-C motif chemokine 17.
Acts as an anti-inflammatory in the gut. May play a role in the innate defense against infections.
Mouse | |
---|---|
Gene Name: | Cxcl17 |
Uniprot: | Q5UW37 |
Entrez: | 232983 |
Belongs to: |
---|
intercrine alpha (chemokine CxC) family |
Chemokine (C-X-C Motif) Ligand 17; C-X-C Motif Chemokine 17; CXCL17; Dcip1; Dendritic Cell And Monocyte Chemokine-Like Protein; DMC; UNQ473; VCC1; VCC-1; VEGF Coregulated Chemokine 1; VEGF Co-Regulated Chemokine 1
Mass (kDA):
13.627 kDA
Mouse | |
---|---|
Location: | 7|7 A3 |
Sequence: | 7; |
Detected in lung, trachea, lung, tongue thyroid, submaxillary gland, epididymis, and uterus tissues and at a lower level in ovary, prostate and in intestinal tissues.
The CXCL17 marker is a cell-based anti-inflammatory drug that you might be interested in. Here are some of the reasons why you should check it out and which uses it has to offer. You will also learn about CXCR4 +EC and how it differs form the Tip cells phenotype.
Human lymphocytes tested positive for CXCL17 mRNA. This molecule is produced in tumor cells, and is a strong prognostic indicator for colorectal carcinoma. It can be detected by measuring the amount of carcinoembryonic antigen messengerRNA. It is at least equal to the hematoxylin/eosin method. CXCL17 was implicated in the antitumour immune reaction during pancreatic carcinomagenesis. It caused the accumulation of tumour cells and increased the susceptibility to cytotoxic-mediated cytolysis by cytotoxic T-cells.
In addition to its role in the immune system, CXCL17 has several potential roles in colon cancer treatment. Its high expression is an early indicator of poor prognosis. It may increase local angiogenesis, draw immune cells, and counteract the growth of tumours. Moreover, CXCL17 is thought to be a bactericidal peptide. CXCL17 may be a biomarker of colon cancer.
To validate the role of this marker for seasonal and pandemic flu, more research is needed. Although the results of the study look promising, further analysis is necessary to confirm its existence. CXCL17 will be expressed in humans and help to identify patients suffering from COVID-19 or Pulmonary Tuberculosis. It may also be useful in determining the inflammatory response to an anti-infective drug or a vaccination.
Interestingly, CXCL17 mRNA expression in lymph nodes has been shown to be a predictive factor of tumor recurrence in patients with non-malignant disease. CXCL17 could be used alongside CEA to identify patients at highest risk of recurrence. It could also be used to identify patients with low CEA levels.
The immune system plays many functions, including the regulation and development of inflammation-related diseases. The most common function is to detect the presence of a bacterial or anti-inflammatory reaction. The immune response might be used as a diagnostic tool to determine the exact causes of an illness. CXCL17 has been detected in post-mortem lung specimens taken from patients with pandemic influenza A (h2N1) and COVID-19. This indicates that the disease may be present in the lung.
Boster Bio: Best Uses For The Cellular component CXCL17 (CCXCL17). It has been shown to be a powerful marker in the treatment for pancreatic, breast and colon cancers. It is also expressed in the tumor microenvironment which is a characteristic associated with cancer. CXCL10 and CXCL17 expression levels were significantly higher in pancreas, breast, and colon cancer cells.
Boster offers high affinity primary antibodies for immunohistochemistry as well as Western Blotting. Boster's antibodies are well-cited in scientific literature and consistently validated. They are also tested to ensure accuracy and reliability. Their specificity and sensitivity have been demonstrated repeatedly. These antibodies can be used confidently. CXCL17 may not always be present in tumor samples. Boster's antigens can be helpful if you are unsure which antigen you should use.
CXCLs can be used as a prognostic indicator for colorectal carcinoma. CXCs can be used in immunotherapy to increase the survival rate of patients with colorectal carcinoma and to detect tumors early. They may also be involved, possibly, in gastrointestinal flora-related diseases. These discoveries are exciting.
The signalling pathway CXCL17/CXCR8 may play a role for colon cancer. These pathways can be used to predict the development and progression colon cancer. CXCL17/CXCR8 could be useful in improving outcomes for patients with advanced colon cancer. This study is an important step in improving the outcomes of patients with colon cancer by studying the interaction between CXCL17 & the signaling pathway.
PMID: 16989774 by Weinstein E.J., et al. VCC-1, a novel chemokine, promotes tumor growth.
PMID: 24973458 by Burkhardt A.M., et al. CXCL17 is a major chemotactic factor for lung macrophages.